Potential Refinement of Recurrence Score by pSTAT3 Status

Albert Grinshpun, Yogev Cohen, Aviad Zick, Luna Kadouri, Tamar Hamburger, Benjamin Nisman, Tanir M. Allweis, Gabriela Oprea, Tamar Peretz, Beatrice Uziely, Amir Sonnenblick*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population.

Original languageAmerican English
Article number438
Issue number3
StatePublished - 27 Feb 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.


  • Early breast cancer
  • Oncotype
  • PSTAT3
  • Prognosis
  • Recurrence score


Dive into the research topics of 'Potential Refinement of Recurrence Score by pSTAT3 Status'. Together they form a unique fingerprint.

Cite this